caa a22 4500 46578948X CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900201xx s 000 0 eng 10.1007/BF00216926 doi (NATIONALLICENCE)springer-10.1007/BF00216926 High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer — a phase II study in elderly patients or patients with cardiac risk [Elektronische Daten] [H. Wilke, P. Preusser, U. Fink, W. Achterrath, L. Lenaz, M. Stahl, C. Schober, H. Link, H. Meyer, B. Lucke, H. Schmoll] Summary: Thirty-four consecutive patients with measurable advanced gastric cancer were treated in a disease oriented Phase II study with high-dose folinic acid (HDFA) 300 mg/m2 10 min. inf., followed immediately by etoposide 120 mg/m2 50 min. inf., followed immediately by 5-fluorouracil (5-FU) 500 mg/m2 10 min. inf., given on day 1,2,3 (ELF). Courses were repeated every 22-28 days. All patients who entered this study were older than 65 years or had underlying cardiac disease. Thirty-three patients were evaluable for response and toxicity (⩾ 1 course). One patient was lost to follow up. The overall response rate was 48% (16/33) including 12% (4/33) complete remissions. Eight patients had minor responses or no change and 9 had progressive disease. Five of six patients with locally advanced and non-resectable disease had an objective response (1 CR, 4 PR's). The response rate in patients with metastatic disease was 41% (11/27). After a median observation time of 6.5 months, the median survival time was 10.5 months, with a median remission (CR + PR) duration of 8 months. Toxicity was manageable and included mild to moderate myelosuppression and gastrointestinal toxicities. One episode of life-threatening (Grade IV) leukopenia, and two episodes of severe diarrhea requiring hydration were noted. No treatment related death occurred. ELF is an effective combination in advanced gastric cancer and can be safely administered to elderly patients and patients with cardiac risk. Kluwer Academic Publishers, 1990 folinic acid nationallicence etoposide nationallicence fluorouracil nationallicence gastric cancer elderly patients nationallicence cardiac risk nationallicence Wilke H. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut Preusser P. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut Fink U. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut Achterrath W. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut Lenaz L. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut Stahl M. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut Schober C. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut Link H. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut Meyer H. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut Lucke B. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut Schmoll H. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 65-70 0167-6997 8:1<65 1990 8 10637 https://doi.org/10.1007/BF00216926 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00216926 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Wilke H. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut NATIONALLICENCE 700 1- Preusser P. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut NATIONALLICENCE 700 1- Fink U. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut NATIONALLICENCE 700 1- Achterrath W. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut NATIONALLICENCE 700 1- Lenaz L. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut NATIONALLICENCE 700 1- Stahl M. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut NATIONALLICENCE 700 1- Schober C. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut NATIONALLICENCE 700 1- Link H. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut NATIONALLICENCE 700 1- Meyer H. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut NATIONALLICENCE 700 1- Lucke B. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut NATIONALLICENCE 700 1- Schmoll H. Departments of Hematology/Oncology and Surgery, Hannover University, Medical School, Hannover aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 65-70 0167-6997 8:1<65 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer